Replies to post #351 on Equity Field Notes from temporal sources

[DanWebzster]

DFFN will be the first Biotech to be sanctioned by the FDA to conduct a trial in the back of ambulances.

DFFN is planning a Ph2 study for its TSC molecule to treat Acute Stroke. The global stroke market has a TAM of $36B

TSC is also being studied to speed diffusion of drug thru solid tumors. DFFN has programs in Glioblastoma, Pancreatic Cancer & Brain Metastases.

Cash runway extends thru H2/19; but, Ph3 study(ies) will require a partnership or significant dilutive financing.